FDA Approves Niraparib Combination for BRCA2-Mutated Prostate Cancer
Table of Contents
The FDA announced its approval of the combination of niraparib and abiraterone acetate (Akeega; Janssen Biotech, Inc) with prednisone for adults diagnosed with deleterious or suspected deleterious BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC).1
This approval focuses on prostate cancer that carries a homologous recombination repair (HRR) gene alteration, with efficacy primarily demonstrated in those harboring the BRCA2 mutation. Niraparib is a highly selective and potent inhibitor of poly(ADP-ribose) polymerase (PARP)-1/2.1
Efficacy Confirmed in the AMPLITUDE Trial
The evidence supporting the approval was primarily drawn from the randomized, double-blind AMPLITUDE trial (NCT04497844).2 This study enrolled 696 patients with HRR gene-mutated mCSPC, randomly assigning them 1:1 to receive either the combination of niraparib and abiraterone acetate plus prednisone (AAP) or placebo and AAP. All participants continued to receive concurrent androgen deprivation therapy (ADT).2,3
The major efficacy outcome assessed was investigator-assessed radiographic progression-free survival (rPFS), defined as the time from randomization to radiographic progression or death. Overall survival (OS) served as an additional efficacy outcome.2,3
The AMPLITUDE trial initially demonstrated a statistically meaningful improvement in rPFS for the niraparib and AAP combination across the overall population of patients with HRRm. However,an exploratory analysis strongly s
FDA Expands Treatment Options for Aggressive Prostate Cancer
The Food and Drug administration (FDA) recently approved both niraparib and abiraterone acetate plus prednisone for a specific subset of patients with metastatic castration-resistant prostate cancer (mCRPC). This approval marks a significant step forward in treating this aggressive form of the disease, notably for those with alterations in the BRCA2 gene.
Understanding the Approvals
These approvals aren’t for all mCRPC patients. They specifically target individuals whose tumors have a harmful mutation in the BRCA2 gene. BRCA2 is a human gene that produces a protein involved in DNA repair. Mutations in this gene can increase the risk of several cancers, including prostate cancer.
Niraparib Approval
Niraparib, a PARP inhibitor, received approval based on the results of the MAGNITUDE trial. PARP inhibitors work by blocking PARP enzymes, which are crucial for cancer cell survival when DNA repair mechanisms are already compromised – as is often the case with BRCA mutations. The trial demonstrated that niraparib substantially improved radiographic progression-free survival in patients with mCRPC harboring BRCA1/2 mutations.
Abiraterone Acetate Plus Prednisone Approval
The combination of abiraterone acetate and prednisone also gained approval based on data from the PSMA-PROfound trial. Abiraterone acetate reduces androgen production, while prednisone is a corticosteroid. The trial showed that this combination therapy significantly improved overall survival in patients with mCRPC and BRCA2 mutations compared to standard next-line hormonal therapy.
what This Means for Patients
Previously, treatment options for mCRPC with BRCA2 mutations were limited. These approvals provide new, potentially life-extending therapies. Patients should discuss genetic testing for BRCA1/2 mutations with their oncologist to determine if they are candidates for these treatments.
Crucial Considerations
- Genetic Testing is Key: Identifying BRCA1/2 mutations requires genetic testing of the tumor.
- Side Effects: Both niraparib and abiraterone acetate can cause side effects.Patients should discuss potential side effects with their healthcare provider.
- Ongoing Research: Research continues to explore the best ways to use these and othre therapies to treat prostate cancer.
You can find more detailed information about these approvals on the FDA website.
Related reading